Role of low-molecular-weight heparins in the management of patients with unstable angina pectoris and non-Q-wave acute myocardial infarction

American Journal of Cardiology

Volumn 85, Issue 8 SUPPL. 1, 2000, Pages 2-9

  Monrad, E Scott ^a  

^a MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DALTEPARIN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ACUTE HEART INFARCTION; ARTICLE; CLINICAL RESEARCH; CLINICAL TRIAL; CORONARY ARTERY DILATATION; COST CONTROL; DRUG CHOICE; DRUG EFFICACY; HEPARINIZATION; HUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

EID: 0034720133     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(00)00879-1     Document Type: Article

References (59)

1. Guetta V., Topol E.J. Pacifying the infarct vessel. Circulation. 96:1997;713-715.
2. Herrick J.B. Clinical features of sudden obstruction of the coronary arteries. JAMA. 59:1912;2015-2020.
3. DeWood M.A., Spores J., Notske R., Mouser L.T., Burroughs R., Golden M.S., Lang H.T. Prevalence of total coronary occlusion during the early hours of transmural MI. N Engl J Med. 303:1980;897-902.
4. Davies M.J. Stability and instability two faces of coronary atherosclerosis . Circulation. 94:1996;2013-2030.
5. Libby P. Molecular basis of the acute coronary syndromes. Circulation. 91:1995;2844-2850.
6. Farb A., Burke A.P., Tang A.L., Liang T.Y., Mannan P., Smialek J., Virmani R. Coronary plaque erosion without rupture into a lipid core. Circulation. 93:1996;1354-1363.
7. Sobel B.E. Increased plasminogen activator inhibitor-1 and vasculopathy. Circulation. 99:1999;2496-2498.
8. Kaartinen M., Penttila A., Kovanen P.T. Mast cells in rupture-prone areas of human coronary atheromas produce and store TNF-alpha. Circulation. 94:1996;2787-2792.
9. Kaartinen M., Penttila A., Kovanen P.T. Accumulation of activated mast cells in the shoulder region of human coronary atheroma, the predilection site of atheromatous rupture. Circulation. 90:1994;1669-1678.
10. Fuster V, Stein B, Ambrose JA, Badimon L, Badimon JJ, Chesebro JH. Atherosclerotic plaque rupture and thrombosis. Circulation 1990;82:(suppl II) II-47-II-59.
11. Ware J.A., Heistad D.D. Platelet-endothelium interactions. N Engl J Med. 328:1993;628-635.
12. Moreno P.R., Bernardi V.H., Lopez-Cuellar J., Murcia A.M., Palacios I.F., Gold H.K., Mehran R., Sharma S.K., Nemerson Y., Fuster V., Fallon J.T. Macrophages, smooth muscle cells, and tissue factor in unstable angina. Circulation. 94:1996;3090-3097.
13. Annex B.H., Denning S.M., Channon K.M., Sketch M.H. Jr, Stack R.S., Morrissey J.H., Peters K.G. Differential expression of tissue factor protein in directional atherectomy specimens from patients with stable and unstable coronary syndromes. Circulation. 91:1995;619-622.
14. Ardissino D., Merlini P.A., Ariens R., Coppola R., Bramucci E., Mannucci P.M. Tissue-factor antigen and activity in human coronary atherosclerotic plaques. Lancet. 349:1997;769-771.
15. Soejima H., Ogawa H., Yasue H., Kaikita K., Nishiyama K., Misumi K., Takazoe K., Miyao Y., Yoshimura M., Kugiyama K., Nakamura S., Tsuji I., Kumeda K. Heightened tissue factor associated with tissue factor pathway inhibitor and prognosis in patients with unstable angina. Circulation. 99:1999;2908-2913.
16. Davies MJ. A macro and micro view of coronary vascular insult in ischemic heart disease. Circulation 1990;82(suppl II):II-38-II-46.
17. Lefkovits J., Plow E.F., Topol E.J. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med. 332:1995;1553-1559.
18. Ott I., Neumann F.-J., Gawaz M., Schmitt M., Schoemig A. Increased neutrophil-platelet adhesion in patients with unstable angina. Circulation. 94:1996;1239-1246.
19. DeWood M.A., Stifter W.F., Simpson C.S., Spores J., Eugster G.S., Judge T.P., Hinnen M.L. Coronary arteriographic findings soon after non-Q wave MI. N Engl J Med. 315:1986;417-423.
20. Sherman CT, Litvack F, Grundfest W, Lee M, Hickey A, Chaux A, Kass R, Blanche C, Matloff J, Morgenstern L, et al. Coronary angioscopy in patients with unstable angina pectoris. N Engl J Med 1986;315:913-919.
21. Oler A., Whooley M.A., Oler J., Grady D. Adding heparin to aspirin reduces the incidence of MI and death in patients with unstable angina a meta-analysis . JAMA. 276:1996;811-815.
22. Weitz J.I. Low-molecular-weight heparins. N Engl J Med. 338:1997;688-698.
23. Agnelli G., Iorio A., Renga C., Boschetti E., Nenci G.G., Ofosu F.A., Hirsh J. Prolonged antithrombin activity of low-molecular-weight heparins. Circulation. 92:1995;2819-2824.
24. Kroon C., ten Hove W.R., de Boer A., Kroon J.M., van der Pol J.M., Harthoorn-Lasthuizen E.J., Schoemaker H.C., van der Meer F.J., Cohen A.F. Highly variable anticoagulant response after subcutaneous administration of high-dose (12,500 IU) heparin in patients with MI and healthy volunteers. Circulation. 86:1992;1370-1375.
25. Delanty N., Fitzgerald D.J. Subcutaneous heparin during coronary thrombolysis. Too little, too late. Circulation. 86:1992;1636-1638.
26. Agnelli G., Iorio A., Renga C., Boschetti E., Nenci G.G., Ofosu F.A., Hirsh J. Prolonged antithrombin activity of low-molecular-weight heparins. Circulation. 92:1995;2819-2824.
27. Hull R.D., Raskob G.E., Brant R.F., Pineo G.F., Elliott G., Stein P.D., Gottschalk A., Valentine K.A., Mah A.F. Low-molecular-weight heparin vs heparin in the treatment of patients with pulmonary embolism. Arch Intern Med. 160:2000;229-236.
28. Dolovich L.R., Ginsberg J.S., Douketis J.D., Holbrook A.M. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism. Arch Intern Med. 160:2000;181-188.
29. Warkentin T.E., Levine M.N., Hirsh J., Horsewood P., Roberts R.S., Gent M., Kelton J.G. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med. 332:1995;1330-1335.
30. Xiao Z., Théroux P. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor. Circulation. 97:1998;251-256.
31. Salzman E.W. Low-molecular-weight heparin Is small beautiful? N Engl J Med. 315:1986;957-959.
32. Verstraete M. Pharmacotherapeutic aspects of unfractionated and low-molecular-weight heparin. Drugs. 40:1990;498-530.
33. Waters D., Azar R.R. Low-molecular-weight-heparins for unstable angina. A better mousetrap? Circulation. 96:1997;3-5.
34. Prager N.A., Abendschein D.R., McKenzie C.R., Eisenberg P.R. Role of thrombin compared with Factor Xa in the procoagulant activity of whole blood clots. Circulation. 92:1995;962-967.
35. Théroux P, Ouimet H, McCans J, Latour JG, Joly P, Levy G, Pelletier E, Juneau M, Stasiak J, deGuise P, et al. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med 1988;319:1105-1111.
36. Neri Serneri G.G., Modesti P.A., Gensini G.F., Branzi A., Melandri G., Poggesi L., Rostagno C., Tamburini C., Carnovali M., Magnani B. Randomized comparison of subcutaneous heparin, intravenous heparin, and aspirin in unstable angina. Lancet. 345:1995;1201-1204.
37. Théroux P., Waters D., Lam J., Juneu M., McCans J. Reactivation of unstable angina after the discontinuation of heparin. N Engl J Med. 327:1992;141-145.
38. Granger CB, Miller JM, Bovill EG, Gruber A, Tracy RP, Krucoff MW, Green C, Berrios E, Harrington RA, Ohman EM, et al. Rebound increase in thrombin generation and activity after cessation of intravenous heparin in patients with acute coronary syndromes. Circulation 1995;91:1929-1935.
39. Fragmin During Instability in Coronary Artery Disease (FRISC) study group. Low-molecular-weight heparin during instability in CAD. Lancet 1996;347:561-568.
40. Klein W, Buchwald A, Hillis SE, Monrad S, Sanz G, Turpie AG, van der Meer J, Olaisson E, Undeland S, Ludwig K, et al for the FRIC Investigators. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable CAD. Circulation 1997;96:61-68.
41. Cohen M., Demers C., Gurfinkel E.P., Turpie A.G., Fromell G.J., Goodman S., Langer A., Califf R.M., Fox K.A., Premmereur J., Bigonzi F. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable CAD. N Engl J Med. 337:1997;447-452.
42. Fragmin and Fast Revascularization during InStability in Coronary artery disease (FRISC II) Investigators. Long-term low-molecular-mass heparin in unstable coronary-artery disease: Frisc II prospective randomized multicentre study. Lancet 1999;354:701-707.
43. Fragmin and Fast Revascularization during InStability in Coronary artery disease (FRISC II) Investigators. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomized multicentre study. Lancet 1999;354:708-715.
44. Gurfinkel E.P., Manos E.J., Mejail R.I., Cerda M.A., Duronto E.A., Garcia C.N., Daroca A.M., Mautner B. Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. J Am Coll Cardiol. 26:1995;313-318.
45. The Thrombolysis in Myocardial Infarction (TIMI) 11A Trial Investigators. Dose-ranging trial of enoxaparin for unstable angina: results of TIMI 11A. J Am Coll Cardiol 1997;29:1474-1482.
46. Glick A., Kornowski R., Michowich Y., Koifman B., Roth A., Laniado S., Keren G. Reduction of reinfarction and angina with use of low-molecular-weight heparin therapy after streptokinase (and heparin) in acute MI. Am J Cardiol. 77:1996;1145-1148.
47. Mark D.B., Cowper P.A., Berkowitz S.D., Davidson-Ray L., DeLong E.R., Turpie A.G., Califf R.M., Weatherley B., Cohen M. Economic assessment of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients. Circulation. 97:1998;1702-1707.
48. Hirsh J. Comparison of the relative efficacy and safety of low molecular weight heparin and unfractionated heparin for the treatment of venous thrombosis. Haemostasis. 26:(suppl 4):1996;189-198.
49. Monrad E.S. Thrombolysis the need for a critical review . J Am Coll Cardiol. 18:1991;1573-1578.
50. Kassirer J.P. Our endangered integrity it can only get worse . N Engl J Med. 336:1997;1666-1667.
51. Laupacis A., Feeny D., Detsky A.S., Tugwell P.X. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J. 146:1992;473-481.
52. Laupacis A., Feeny D., Detsky A.S., Tugwell P.X. Tentative guidelines for using clinical and economic evaluations revisited. Can Med Assoc J. 148:1993;927-929.
53. Antman EM, McCabe CH, Gurfinkel EP, Turpie AG, Bernink PJ, Salein D, Bayes De Luna A, Fox K, Lablanche JM, Radley D, Premmereur J, Braunwald E. Enoxaparin prrevents death and cardiac ischemic events in unstable angina/non-Q-wave MI. Circulation 1999;100:1593-1601.
54. Marmur J.D., Thiruvikraman S.V., Fyfe B.S., Guha A., Sharma S.K., Ambrose J.A., Fallon J.T., Nemerson Y., Taubman M.B. Identification of active tissue factor in human coronary atheroma. Circulation. 94:1996;1226-1232.
55. Faxon DP, Spiro TE, Minor S, Cote G, Douglas J, Gottlieb R, Califf R, Dorosti K, Topol E, Gordon JB, et al. Low molecular weight heparin in prevention of restenosis after angioplasty. Circulation 1994;90:908-914.
56. Cairns J.A., Gill J., Morton B., Roberts R., Gent M., Hirsh J., Holder D., Finnie K., Marquis J.F., Naqvi S., Cohen E. Fish oils and low-molecular-weight heparin for the reduction of restenosis after percutaneous transluminal coronary angioplasty. Circulation. 94:1996;1553-1560.
57. Lablanche J.M., McFadden E.P., Meneveau N., Lusson J.R., Bertrand B., Metzger J.P., Legrand V., Grollier G., Macaya C., de Bruyne B., et al. Effect of nadroparin, a low-molecular-weight heparin, on clinical and angiographic restenosis after coronary balloon angioplasty. Circulation. 96:1997;3396-3402.
58. Brack MJ, Ray S, Chauhan A, Fox J, Hubner PJ, Schofield P, Harley A, Gershlick AH. The Subcutaneous Heparin and Angioplasty Restenosis Prevention (SHARP) Trial. J Am Coll Cardiol 1995;26:947-954.
59. Serruys PW, Herrman JP, Simon R, Rutsch W, Bode C, Laarman GJ, van Dijk R, van den Bos AA, Umans VA, Fox KA, et al. A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. N Engl J Med 1995;333:757-763.